NCT06963034 - NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Biotech Hunter

Enrollment

284

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Schizophrenia

Interventions

DRUG

NBI-1117568

NBI-1117568 will be administered per schedule specified in the arm description.

DRUG

Placebo

Placebo will be administered per schedule specified in the arm description.

Trial Locations (16)

10314

RECRUITING

Neurocrine Clinical Site, Staten Island

20877

RECRUITING

Neurocrine Clinical Site, Gaithersburg

30030

RECRUITING

Neurocrine Clinical Site, Decatur

30331

RECRUITING

Neurocrine Clinical Site, Atlanta

33016

RECRUITING

Neurocrine Clinical Site, Miami Lakes

33024

RECRUITING

Neurocrine Clinical Site, Hollywood

60640

RECRUITING

Neurocrine Clinical Site, Chicago

72211

RECRUITING

Neurocrine Clinical Site, Little Rock

78754

RECRUITING

Neurocrine Clinical Site, Austin

90504

RECRUITING

Neurocrine Clinical Site, Torrance

90660

RECRUITING

Neurocrine Clinical Site, Pico Rivera

91403

RECRUITING

Neurocrine Clinical Site, Sherman Oaks

92123

RECRUITING

Neurocrine Clinical Site, San Diego

92805

RECRUITING

Neurocrine Clinical Site, Anaheim

02472

RECRUITING

Neurocrine Clinical Site, Watertown

08053

RECRUITING

Neurocrine Clinical Site, Marlton